Polarean notes statement from Amphion Innovations

RNS Number : 5457N

Polarean Imaging PLC

25 September 2019

 

Polarean Imaging Plc 

("Polarean" or the "Company")

Polarean notes statement from Amphion Innovations

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender"). 

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020.  No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries: 

Polarean Imaging plc			www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer				Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP				Tel: [phone]
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy / Paul McManus		Mob: [phone]

 

END

 

 

MSCEAANLAALNEAF